[go: up one dir, main page]

AR095338A1 - Método de tratamiento no tóxico para la abstinencia de drogas - Google Patents

Método de tratamiento no tóxico para la abstinencia de drogas

Info

Publication number
AR095338A1
AR095338A1 ARP140101042A ARP140101042A AR095338A1 AR 095338 A1 AR095338 A1 AR 095338A1 AR P140101042 A ARP140101042 A AR P140101042A AR P140101042 A ARP140101042 A AR P140101042A AR 095338 A1 AR095338 A1 AR 095338A1
Authority
AR
Argentina
Prior art keywords
treatment method
toxic treatment
drug abstinence
withdrawal
noribogaine
Prior art date
Application number
ARP140101042A
Other languages
English (en)
Inventor
Friedhoff Lawrence
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of AR095338A1 publication Critical patent/AR095338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un método para el tratamiento de los síntomas de abstinencia en un paciente que padece de abstinencia de la adicción a una sustancia, que comprende la administración al paciente de una dosis de noribogaína que provee una Cₘₐˣ de noribogaína de menos de aproximadamente 1980 ng/mg de suero y una AUC/24 hs promedio de aproximadamente 1.100 ng/ml.
ARP140101042A 2013-03-15 2014-03-14 Método de tratamiento no tóxico para la abstinencia de drogas AR095338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361852485P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095338A1 true AR095338A1 (es) 2015-10-07

Family

ID=51537436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101042A AR095338A1 (es) 2013-03-15 2014-03-14 Método de tratamiento no tóxico para la abstinencia de drogas

Country Status (14)

Country Link
US (3) US20160271139A1 (es)
EP (1) EP2968355A4 (es)
JP (1) JP2016514679A (es)
KR (1) KR20150130461A (es)
CN (1) CN105307658A (es)
AR (1) AR095338A1 (es)
AU (1) AU2014228986A1 (es)
BR (1) BR112015022465A2 (es)
CA (3) CA3256416A1 (es)
EA (1) EA201591679A1 (es)
HK (1) HK1220381A1 (es)
TW (1) TW201505634A (es)
WO (2) WO2014143201A1 (es)
ZA (1) ZA201507514B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
KR20160120781A (ko) 2014-02-18 2016-10-18 데메알엑스, 인크. 약물 중독의 급성 및 장기간 치료 방법
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
EP3107546A4 (en) * 2014-02-18 2017-10-25 DemeRx, Inc. Therapeutic methods employing noribogaine and related compounds
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2016086194A1 (en) 2014-11-26 2016-06-02 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) * 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors
WO2016183244A1 (en) * 2015-05-11 2016-11-17 Demerx, Inc. Methods for treatment of opioid dependency and withdrawal using noribogaine
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102409785B1 (ko) 2017-03-23 2022-06-16 삼성전자주식회사 무선 통신 시스템에서 초기 접속을 수행하기 위한 장치 및 방법
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220265675A1 (en) * 2019-07-15 2022-08-25 Demerx, Inc. Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2817623A (en) 1956-03-22 1957-12-24 Ciba Pharm Prod Inc Tabernanthine, ibogaine containing analgesic compositions
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
ES2264562T3 (es) * 1994-07-25 2007-01-01 Nda International, Inc. Uso de derivados de noribogaina para tratar la dependencia quimica en mamiferos.
US5591738A (en) 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5616575A (en) 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6416793B1 (en) 2000-07-11 2002-07-09 Bioresponse, L.L.C. Formulations and use of controlled-release indole alkaloids
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US6939538B2 (en) * 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CN103079571A (zh) 2010-07-23 2013-05-01 德莫科斯公司 降伊波加因碱组合物
EP2605813B1 (en) 2010-08-17 2018-08-01 University of Florida Research Foundation, Inc. Intelligent drug delivery system to optimizing medical treatment or therapy.
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
WO2013040471A2 (en) 2011-09-15 2013-03-21 Demerx, Inc. Noribogaine salt ansolvates
EP2788355A4 (en) 2011-12-08 2015-10-21 Demerx Inc STEREOSELECTIVE TOTAL SYNTHESIS OF NORIBOGAIN
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
CA2855990A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Sulfate esters of noribogaine
CA2857969A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2693223B8 (en) 2012-08-03 2021-09-08 ABB Schweiz AG Voltage measurement device with an insulating body
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
KR20160120781A (ko) 2014-02-18 2016-10-18 데메알엑스, 인크. 약물 중독의 급성 및 장기간 치료 방법
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
EP3107546A4 (en) 2014-02-18 2017-10-25 DemeRx, Inc. Therapeutic methods employing noribogaine and related compounds
US20150246055A1 (en) 2014-03-03 2015-09-03 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
US20150258108A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics
US20150258107A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for treating depression
US20150258105A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US20150258106A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse
US20150258111A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
WO2015163844A1 (en) 2014-04-21 2015-10-29 Demerx, Inc. N-substituted noribogaine prodrugs
US20150342959A1 (en) 2014-06-03 2015-12-03 Demerx, Inc. Methods and compositions for sustained noribogaine treatment
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
WO2016086194A1 (en) 2014-11-26 2016-06-02 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
US20150045350A1 (en) 2015-02-12
EP2968355A2 (en) 2016-01-20
CA2942511A1 (en) 2014-09-18
EA201591679A1 (ru) 2016-05-31
WO2014144508A2 (en) 2014-09-18
WO2014143201A1 (en) 2014-09-18
CA2942638A1 (en) 2014-09-18
ZA201507514B (en) 2018-05-30
CN105307658A (zh) 2016-02-03
TW201505634A (zh) 2015-02-16
US9744174B2 (en) 2017-08-29
JP2016514679A (ja) 2016-05-23
US20140288056A1 (en) 2014-09-25
US20160271139A1 (en) 2016-09-22
CA3256416A1 (en) 2025-06-21
KR20150130461A (ko) 2015-11-23
AU2014228986A1 (en) 2015-10-29
EP2968355A4 (en) 2016-08-24
BR112015022465A2 (pt) 2017-07-18
HK1220381A1 (zh) 2017-05-05

Similar Documents

Publication Publication Date Title
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2016004316A (es) Inhalador de polvo seco.
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
AR104771A1 (es) Inhalador de polvo seco
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112015012497A2 (pt) combinações farmacêuticas
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
CL2012002942A1 (es) Uso de un derivado sintetico de retinol e hidroxianisol butilado disuelto en aceite de soya para preparar un medicamento util en el tratamiento de un sujeto humano que sufre de la perdida o el deterioro de la vison causado por un trastorno por deficencia de retinol 11-cis producido endogenamente; composicion farmeceutica.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
AR102903A1 (es) Inhalador de polvo seco
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.

Legal Events

Date Code Title Description
FB Suspension of granting procedure